New integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.
Read articleNew integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.
ReadIn the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.
ReadLaunch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.
ReadPaper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.
ReadAddition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.
ReadNew content and Interpret NGS analysis software detection capabilities include BCR-ABL and KMT2A-PTD detection.
ReadDuring these unprecedented times, OGT remains committed and ready to support you...
ReadReinforcing collaboration toward the realization of genomic medicine in the area of ophthalmic disorders.
ReadPlasma and tissue sequencing demonstrate clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment.
ReadRobust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.
ReadSureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay.
ReadCytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.
Read
